Bacteremia due to Methicillin-Resistant Staphylococcus aureus: New Therapeutic Approaches.

Related Articles

Bacteremia due to Methicillin-Resistant Staphylococcus aureus: New Therapeutic Approaches.

Infect Dis Clin North Am. 2016 Jun;30(2):491-507

Authors: Holubar M, Meng L, Deresinski S

Abstract
This article reviews recent clinical evidence for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. Vancomycin remains the initial antibiotic of choice for the treatment of patients with MRSA bacteremia and endocarditis due to isolates with vancomycin minimum inhibitory concentration ≤2 μg/mL, whereas daptomycin is an effective alternative, and ceftaroline seems promising. Treatment options for persistent MRSA bacteremia or bacteremia due to vancomycin-intermediate or vancomycin-resistant strains include daptomycin, ceftaroline, and combination therapies. There is a critical need for high-level evidence from clinical trials to allow optimally informed decisions in the treatment of MRSA bacteremia and endocarditis.

PMID: 27208769 [PubMed - in process]